Daiichi Sankyo and BMS to perform Phase Ib oncology combination trial

Daiichi Sankyo has entered a research collaboration to assess its investigational antibody drug conjugate (ADC) DS-8201 in combination with Bristol-Myers Squibb ’s (BMS) Opdivo (nivolumab) in a Phase Ib clinical trial to treat HER2-expressing metastat…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news